MYDA Advisors’s Harmony Biosciences HRMY Stock Holding History

MYDA Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-32,782	Closed	-$1.11M	–	210
2020 Q3	$1.11M	Buy	+32,782	New	+$1.2M	0.58%	45

Other funds holding HRMY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MYDA Advisors's HRMY Position: Q4 2020 in Review

MYDA Advisors sold out of Harmony Biosciences (HRMY) in Q4 2020, closing a stake of 32,782 shares — an estimated $1.11M sold.

MYDA Advisors first reported a position in HRMY in Q3 2020 and held it in 1 quarter. The position peaked at $1.11M in Q3 2020. 59 funds tracked by Wall St. Rank hold HRMY as of Q4 2020.

MYDA Advisors reported no remaining Harmony Biosciences position as of Q4 2020 after selling out during the quarter.
MYDA Advisors sold 32,782 Harmony Biosciences shares in Q4 2020, an estimated $1.11M.
MYDA Advisors first reported a position in Harmony Biosciences in Q3 2020 and held it in 1 quarter.
MYDA Advisors's Harmony Biosciences position peaked at $1.11M in Q3 2020.
59 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2020.

Based on MYDA Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.